Strides Pharma Science

Strides Pharma Science Shareholder Yield

The Shareholder Yield of Strides Pharma Science (STAR.NS) as of Oct 16, 2026 is 0.37 %. In the previous year, Shareholder Yield was 0.84 % — a change of -56.05% (lower).

Shareholder Yield

0.37 %

YoY

-56.05%

Last updated:

Shareholder Yield of Strides Pharma Science is 2025 0.37 % . Shareholder Yield of Strides Pharma Science was 2024 0.84 % . It decreases by -56.05% lower compared to the previous year.

The Strides Pharma Science Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2018
0.61 INR
Jan 1, 2019
0.29 INR
Jan 1, 2020
1.95 INR
Jan 1, 2021
0.27 INR
Jan 1, 2022
0.33 INR
Jan 1, 2023
0.49 INR
Jan 1, 2024
0.84 INR
Jan 1, 2025
0.37 INR
The Strides Pharma Science Shareholder Yield history
YEARShareholder YieldYoY
0.37 %-56.05%
0.84 %+72.07%
0.49 %+47.67%
0.33 %+20.66%
0.27 %-86.02%
1.95 %+582.76%
0.29 %-53.05%
0.61 %-19.39%
0.76 %-95.22%
15.83 %+90.01%
8.33 %-78.17%
38.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd, trading under the ticker symbol STAR.NS and identified by ISIN INE939A01011, is a prominent entity within the Indian healthcare sector, specifically operating in the pharmaceuticals industry. Headquartered in Bangalore, Karnataka, the company has established itself as a significant player in the global market for generic and bio-pharmaceutical products. Strides Pharma Science Ltd went public on February 3, 2000, marking a pivotal moment in its corporate history and allowing it to expand its operational footprint. The organization currently employs approximately 2,850 full-time staff members who are dedicated to the development, manufacture, and distribution of its diverse product portfolio. The company’s business activities are primarily divided into two main segments: Pharmaceutical and Bio-pharmaceutical. This structural division allows the firm to focus on both traditional generic drugs and more complex biological therapeutics, ensuring a balanced approach to meeting varied market demands. Geographically, Strides Pharma Science Ltd has a broad international presence, serving markets across Africa, Australia, Asia excluding India, North America, Europe, India, and other regions. This extensive reach is supported by a robust manufacturing infrastructure comprising eight distinct units. These facilities are strategically located to optimize supply chain efficiency and regulatory compliance. In India, the company operates two manufacturing sites in Bengaluru, along with additional facilities in Puducherry and Chennai. Beyond its domestic operations, Strides maintains manufacturing capabilities in Singapore, Milan, Italy, Florida, United States, and Nairobi, Kenya. This global network enables the company to produce a wide array of dosage forms, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release formats. Notably, the company is also engaged in the specialized manufacturing of soft gelatin capsules. The firm’s product development strategy emphasizes intellectual property-led niche products, distinguishing it from competitors who may focus solely on standard generics. The therapeutic areas covered by Strides Pharma Science Ltd are extensive, with a strong emphasis on drugs for anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, as well as other infectious diseases. This focus on high-impact therapeutic segments underscores the company’s commitment to addressing critical global health challenges. By combining a strong manufacturing base with a diverse product range and a global distribution network, Strides Pharma Science Ltd continues to play a vital role in the pharmaceutical landscape, providing essential medicines to patients worldwide while maintaining its position as a key player in the Indian stock market. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Shareholder Yield of Strides Pharma Science is 0.37 % in 2025.

Shareholder Yield of Strides Pharma Science changed from 0.84 % to 0.37 %, representing a -56.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Strides Pharma Science

All Key Metrics — Strides Pharma Science